What is the current value and expected growth of the biobetters market?

The biobetters market stands at USD 62.18 billion in 2025 and is forecast to reach USD 93.58 billion by 2030, advancing at an 8.52% CAGR. Read More

Which drug class holds the largest share of the biobetters market?

Insulin leads the drug-class landscape with 46.23% share thanks to its critical role in diabetes care and the technical complexity that favors differentiated products. Read More

Why are monoclonal antibodies the fastest-growing segment?

Breakthrough antibody-drug conjugate technologies and site-specific protein engineering are lifting monoclonal antibodies at a 10.34% CAGR by improving tumor targeting and safety profiles. Read More

Which region is expanding the quickest and what drives its momentum?

Asia-Pacific is growing at a 9.68% CAGR, fueled by regulatory modernization, new biomanufacturing capacity, and rising healthcare spending in China, Japan, and South Korea. Read More

What is the primary commercial hurdle for biobetter developers in mature markets?

Intensifying price competition from biosimilars forces biobetter sponsors to prove clear clinical advantages that justify premium pricing within payer negotiations. Read More

Biobetters Companies

This report lists the top Biobetters companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Biobetters industry.

Global Biobetters Market

Access Report

About This Report
- Market Size & Share
- Market Analysis
- Trends and Insights
- Segment Analysis
- Geography Analysis
- Competitive Landscape
- Major Players
- Recent Developments
Table of Contents
SCOPE OF THE REPORT
Market Definition